Ab­b­Vie taps Jen­nifer Doud­na start­up for li­cens­ing deal worth up to $300M for 2 'off-the-shelf' CRISPR-edit­ed CAR-Ts

“Off-the-shelf” CAR-Ts have emerged as a hot-tick­et tar­get in next-gen on­col­o­gy R&D, with Big Phar­mas plac­ing big down pay­ments on nov­el tech. Now, a Cal­i­for­nia biotech play­er found­ed by one of the CRISPR move­ment’s most promi­nent mouth­pieces has added ma­jor drug­mak­er Ab­b­Vie as a team­mate.

Ab­b­Vie will pay Cari­bou Bio­sciences $40 mil­lion in up­front cash and $300 mil­lion in biobucks to de­vel­op two of the biotech’s al­lo­gene­ic CAR-T ther­a­pies, the part­ners said Wednes­day. The biotech will al­so be due roy­al­ty pay­ments for any fu­ture com­mer­cial as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER